Application of miR-31-5p in acute myelogenous leukemia

A pre-mir-31, acute myeloid technology, applied in the application field of miR-31-5p in the diagnosis and treatment of acute myeloid leukemia, can solve the problem of increased relapse rate of leukemia patients, and achieve the effect of prolonging life
CN113584166APending Publication Date: 2021-11-02JINAN UNIVERSITY
9 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
JINAN UNIVERSITY
Publication Date
2021-11-02

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to application of miR-31-5p in acute myelogenous leukemia, in particular to application of a product for detecting the miR-31-5p in preparation of a reagent, a chip or a kit for auxiliary diagnosis of subjects suffering from acute myelogenous leukemia (AML) and / or prognosis of the lifetime of the subjects. The invention also relates to an application of the miR-31 initial / precursor miRNA (prime / pre-miR-31) and / or the miR-31 mature miRNA (miR-31-5p) in preparation of a medicine for treating AML (acute myeloid leukemia). The miR-31-5p is introduced into cells through a gene transduction method, so bone marrow AML cells and leukemia stem cells (AML-LSC) can be induced to die, and the cytotoxicity of the chemotherapeutic drug cytarabine is enhanced; by expressing the miR-31-5p, the growth of AML cells and AML-LSC cells can be inhibited, and the life of animals can be prolonged. The disclosure provides a new method for diagnosis and prognosis evaluation of AML, and also provides a gene therapy drug for preparing AML.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The present disclosure is in the field of biomedicine, it relates to the diagnosis and treatment of tumors, particularly to the use of miR-31-5p in acute myeloid leukemia (AML) in diagnosis and treatment. Background technique

[0002] Leukemia is a type of clonal origin of hematopoietic stem cells of malignant disease, according to statistics, currently there are about 35 million people worldwide died of leukemia each year. Therefore, leukemia cancer has become the main current threat to human health. Leukemic stem cells (1eukemia stem cells, LSC) are present in a patient group of a trace amount of leukemic cell population, about 0.1% to 1% of all leukemic cells. LSC was first found in acute myeloid leukemia (AML) and has been widely recognized. Whether the long-term cell culture or in vivo animal models, and to maintain the LSC can cause leukemia; simultaneously, with different leukemia cells, more than 95% of the G0 state LSC "sleep", these cells periodic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More